While T cells engineered with chimeric antigen receptors (CAR-T cells) have revolutionized the landscape of hematologic malignancy treatment, their efficacy against solid tumors remains limited. [...]
Acute myeloid leukemia (AML) is a neoplastic process characterized by its aggressive nature and limited treatment options. Too many AML patients are unable to achieve [...]
Glioblastoma multiforme (GBM), the deadliest malignant brain tumor, also represents a large proportion of all cerebral neoplasms1. Despite strides in immunotherapy, including Chimeric Antigen Receptor [...]
[Longmont, CO. February 6, 2024] —A Stony Brook University team of researchers led by Gábor Balázsi, PhD, has identified DNA amplification as a major cause [...]
Adoptive cell therapies like those based on CAR-T cells have demonstrated remarkable success against several different cancer types, even in advanced cases. Targeted diagnoses include [...]
Despite significant strides in genetic research, we lack a clear understanding of whether many rare diseases may have genetic origins, and of what those origins [...]
DNA double-strand breaks (DSBs) and potential misrepair events can result from the use of gene editing tools like CRISPR/Cas systems. These misrepairs are associated with [...]
In the context of gene editing applications, genotoxicity may be defined as, “the property of an agent able to alter the genetic function within a [...]
Register below for the KromaTiD Webinar | Combining Synthetic and Evolutionary Biology Reveals DNA Therapy to Combat Cancer Chemoresistance Drug resistance is still an ongoing [...]
CAR T cell therapies have achieved substantial improvements in the prognoses of patients fighting advanced hematological malignancies, demonstrating robust efficacy in inducing durable remissions. While [...]
